Trial Profile

Effects of Hypericum Perforatum (St. John's Wort) on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Humans

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Hypericum
Indications Acute coronary syndromes; Arterial thrombosis; Cardiovascular disorders; Coronary thrombosis; Deep vein thrombosis; Embolism; Heart failure; Peripheral arterial disorders; Pulmonary embolism; Stroke; Thromboembolism; Thrombosis; Venous thromboembolism; Venous thrombosis
Focus Pharmacodynamics; Pharmacokinetics

Most Recent Events

22 Sep 2020 Results published in the British Journal of Clinical Pharmacology
06 May 2019 Status changed from recruiting to completed.
11 Jan 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com